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Letter to the Editor 
Clinical Chemistry
Lipoprotein X Detected in a Case of 
Hypercholesterolemia Associated With Chronic 
Cholangiohepatitis 
Jihye Ha, M.D., Sang-Guk Lee, M.D., and Jeong-Ho Kim, M.D.
Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea
Dear Editor,
Lipoprotein X (Lp-X) is a lamellar spherical particle rich in phos-
pholipids and unesterified cholesterol. Although the pathogene-
sis of Lp-X formation is not fully understood in cholestasis, it is 
suggested that lipoprotein in bile refluxes into the plasma and 
binds to albumin forming Lp-X [1]. Lp-X is also found in familial 
lecithin cholesterol acyltransferase (LCAT) deficiency. Thus, it 
has been supposed that reduced LCAT activity, common in pa-
tients with a hepatocellular disease, contributes to Lp-X accu-
mulation in cholestasis [2]. Serum Lp-X detection is a specific 
and sensitive index of cholestasis. Lp-X tests were positive in 
82–100% of patients with histological evidence of cholestasis 
and negative in 95–98.7% of patients whose histological exami-
nation was negative [3-5]. Furthermore, Lp-X may play an im-
portant role in the development of hypercholesterolemia through 
failure to exert negative feedback on cholesterol synthesis [6]. 
Here, we report the first case in Korea that describes the pres-
ence of Lp-X in the serum of a patient with persistent hypercho-
lesterolemia associated with bile obstruction. 
A 71-yr-old woman, with a history of hypertension, diabetes, 
and Wegener’s granulomatosis, was admitted to the hospital 
complaining of dyspnea. Approximately four months earlier, she 
had undergone endoscopic retrograde cholangiopancreatogra-
phy for the removal of distal common bile duct stones developed 
owing to cholangiohepatitis.
Radiological investigation showed newly developed ground 
glass opacity in both lungs. Initial laboratory findings suggested 
acute inflammation—white blood cells, 10.47×109/L; C-reactive 
protein, 82.8 mg/L (reference range<8.0). PCR result for Pneu-
mocystis jirovecii using sputum sample was positive, and the 
patient was diagnosed as having P. jirovecii pneumonia. During 
antibiotic treatment, her pulmonary symptoms and elevated in-
flammation markers resolved gradually. However, her lipid pro-
file and cholestatic markers were abnormal as given below: cho-
lesterol, 13.8 mmol/L (3.7–6.2); LDL-cholesterol, 5.8 mmol/L 
(1.8–4.1); HDL-cholesterol, 1.5 mmol/L (1.0–1.9); triglyceride, 
2.1 mmol/L (0.5–2.3); γ-glutamyltransferase 979 U/L, (7.0–35.0); 
total bilirubin, 80.4 µmol/L (6.8–25.7); alkaline phosphatase, 
1,285 U/L (40–126). Abdominopelvic computed tomography 
revealed intrahepatic duct and common bile duct dilatation, sug-
gesting unresolved cholestasis. The patient was on sulfamethox-
azole/trimethoprim, teicoplanin, ranitidine hydrochloride, mag-
nesium oxide, and calcium polycarbophil medication. Because 
her hypercholesterolemia was assumed to be secondary owing 
to cholestasis, lipoprotein was electrophoresed on agarose gel at 
pH 7.5 using an automated electrophoresis system Hydrasys 
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(Sebia, Norcross, GA, USA), which showed the presence of Lp-X 
(Fig. 1) and indicated that the main etiology of hypercholesterol-
emia in this patient was cholestasis. After five months, her hy-
percholesterolemia was slightly improved, the total bilirubin level 
nearly normalized (1.6 mg/dL), the follow-up lipoprotein electro-
phoresis showed an absence of Lp-X, and the lipid profile was 
as follows: cholesterol, 12.1 mmol/L; LDL-cholesterol, 3.6 mmol/
L; HDL-cholesterol, 2.2 mmol/L; triglyceride, 1.5 mmol/L. After 
one year, her cholesterol was further decreased to 7.2 mmol/L 
and other lipid profile parameters were also improved as follows: 
LDL-cholesterol, 3.0 mmol/L; HDL-cholesterol, 1.9 mmol/L; tri-
glyceride, 0.7 mmol/L.
Lipoprotein electrophoresis also indicated the presence of slow 
alpha HDL (Fig. 1). This abnormal alpha band has been observed 
previously in cases of cholestasis with both increased and de-
creased HDL-cholesterol concentrations [7, 8]. Slow alpha HDL 
has a particle size intermediate to that of normal LDL and HDL. 
In cholestasis, this change in HDL causes discrepancies in HDL 
levels measured by using various methods [9]. In this case, HDL-
cholesterol level was 1.8 mmol/L at admission and gradually in-
creased to 2.8 mmol/L at outpatient follow-up testing three months 
later. We performed LDL sub-fraction electrophoresis (Lipoprint 
LDL System; Quantimetrix, Redondo Beach, CA, USA), to iden-
tify and quantitatively score LDL components according to parti-
cle size, which showed an additional large, abnormal HDL sub-
fraction that seemed to be slow alpha HDL and could be the 
main cause of the abnormally elevated HDL-cholesterol level in 
our patient (Fig. 2).
In addition, the patient was found to be hyponatremic (126 
mmol/L). Pseudohyponatremia has been described in some pa-
tients with severe hypercholesterolemia secondary to increased 
Lp-X [10]. While severe hyperglycemia is known to also cause 
pseudohyponatremia, the patient’s glucose level was 6.7 mmol/
L (3.9–6.1). In this case, the sodium concentration was measured 
by an indirect ion-selective electrode method. Indirect methods 
may underestimate the sodium concentration because of the 
dilution artifacts in patients with hypercholesterolemia.
This is the first case report in Korea that describes the pres-
ence of Lp-X in the serum of a patient with persistent hypercho-
lesterolemia associated with bile obstruction. The cholesterol 
level was normalized after improvement of cholestasis. Lp-X de-
tection could be helpful in determining the cause of hypercho-
lesterolemia in patients with cholestasis.
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